Grab Holdings Ltd. vs Novo Nordisk A/S — how do they compare? Grab Holdings Ltd. trades at $3.63 (market cap $15.26B), while Novo Nordisk A/S trades at $46.22 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 13.6× Grab Holdings Ltd.'s market cap, and Novo Nordisk A/S pays a 3.81% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| GRAB | NVO | |
|---|---|---|
Market Cap | $15.26B | $207.85B |
Sector | Technology | Health |
52-Week High | $6.45 | $63.98 |
52-Week Low | $3.27 | $35.29 |
Enterprise Value | $10.99B | $222.55B |
Dividend Yield | — | 3.81% |
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.625, down 1.23% on the day, showing strong fundamental momentum with three consecutive quarterly earnings beats and a significant turnaround to profitability. The company reported Q2 2026 EPS of $0.06 versus $0.05 expected, with revenue growth accelerating to $3.37 billion in 2025. Technical indicators show a bullish trend with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions near-term.
GRAB presents a compelling growth story with improving profitability and strong analyst support (91.67% buy ratings). The company's raised 2026 guidance and expanding super app ecosystem signal continued momentum. Key risks include volatile cash flow patterns, competitive pressures in Southeast Asia, and recent insider selling activity that warrants monitoring.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Trailing returns across standard periods
Latest headlines on both assets
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →